Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Pharmacology
Reference18 articles.
1. Thrul J, Garcia-Romeu A. Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs Educ Prev Policy. 2021;28:211–4.
2. Williams MT, Davis AK, Xin Y, Sepeda ND, Grigas PC, Sinnott S, et al. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs Educ Prev Policy. 2021;28:215–26.
3. Jones GM, Nock MK. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and sociality. Nat Sci Rep. 2022;12:16976.
4. Garcia-Romeu A, Barrett FS, Carbonaro TC, Johnson MW, Griffith RR. Optimal dosing for psilocybin pharmacotherapy: considering weight-adjusted and fixed dosing approaches. J Psychopharmacol. 2021;35:353–61.
5. Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18:245.